CVRx, Inc. develops and commercializes Barostim, an implantable neuromodulation therapy used to treat heart failure patients, particularly those with HFrEF and a narrow QRS complex. The company sells primarily to hospitals, with U.S. commercialization handled through a direct sales force and European sales supported by direct teams in Germany and distributors in selected countries. Its business is built around physician education, clinical adoption, reimbursement support, and patient identification, rather than high-volume consumer sales. CVRx is still in an expansion phase, with management focused on growing U.S. commercial coverage and broadening the clinical use of Barostim over time. The company also invests in product development to improve Barostim and explore additional cardiovascular indications such as hypertension and arrhythmias.
−89,2 %
85,3 %
−94,1 %
+10,4 %
7.63
6.72
| % | |
|---|---|
| Implantable neuromodulation therapy | 100% Barostim is the core implantable device therapy used to treat selected heart failure patients. |
| Commercial support and adoption services | 0% Clinical education, reimbursement support, and patient identification services that help hospitals adopt Barostim. |
CVRx sells primarily to hospitals and implanting centers that treat heart failure patients and perform Barostim...
Buy Barostim for commercial implantation in heart failure patients and rely on reimbursement support and clinical training.
Purchase Barostim through direct sales in Germany and distributors in other European countries, with adoption shaped by local pricing and regulatory requirements.
Do not buy the device directly, but they are critical decision-makers who evaluate clinical evidence and determine patient eligibility.
Resell Barostim in selected European markets and help extend geographic reach where CVRx does not sell directly.
CVRx generates most of its revenue in the United States, where it has a direct sales organization and where management...
CVRx’s near-term strategy is to expand its U.S. direct sales force and deepen penetration at high-volume cardiology...
The U.S. is the main revenue engine, and more sales territories and active implanting centers should increase Barostim adoption.
Barostim adoption depends on physician confidence, referral flow, and patient identification in a specialized treatment pathway.
New indications could expand the addressable market and reduce reliance on a single heart-failure segment.
CVRx faces execution risk because its business depends on building a specialized sales organization and convincing...
The company expects continued sales, marketing, regulatory, and R&D spending before reaching scale, which can pressure liquidity and investor confidence.
Barostim adoption depends on hospital reimbursement economics; lower coverage or cost containment could reduce procedure volumes.
Growth depends on hiring, training, and retaining specialized medical device sales personnel and expanding active implanting centers.
Barostim competes with other device-based therapies, and future indications require successful clinical trials and regulatory approvals.
Failure to comply with foreign device regulations, including MDR, could restrict sales or increase compliance costs.
LIVN · Electromedical & Electrotherapeutic Apparatus
LivaNova PLC is a medical technology company focused on therapies for cardiac and neurological conditions.
IRIX · Electromedical & Electrotherapeutic Apparatus
IRIDEX Corp is an ophthalmic medical technology company that develops and commercializes laser-based systems and related therapies for sight-threatening eye diseases.
ATRC · Surgical & Medical Instruments & Apparatus
AtriCure designs and sells surgical devices used by cardiac surgeons and electrophysiologists to treat atrial fibrillation, manage the left atrial appendage, and reduce post-operative pain.
VRTX · Pharmaceutical Preparations
Vertex Pharmaceuticals is a U.S.-based biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases.
VTAK · Surgical & Medical Instruments & Apparatus
CVKD · Pharmaceutical Preparations
: 28/04/2026